수의용 정위 방사선 수술 시스템 시장 : 제품 유형, 기술, 대상 동물, 치료법, 최종 사용자별 예측(2026-2032년)

The Veterinary Stereotactic Radiosurgery System Market is projected to grow by USD 9.44 billion at a CAGR of 13.34% by 2032.

The veterinary stereotactic radiosurgery system market is advancing as specialty hospitals, university veterinary centers, and referral oncology practices adopt precision radiation platforms for canine and feline tumors that are difficult to manage with conventional surgery or fractionated radiotherapy. Veterinary stereotactic radiosurgery, also described in clinical use as stereotactic radiation therapy or stereotactic body radiation therapy, combines high-resolution CT and MRI-based treatment planning, immobilization, image guidance, and linear accelerator delivery to concentrate radiation on a defined tumor volume while limiting dose to surrounding normal tissue.

Demand is supported by the well-documented burden of companion animal cancer. The American Veterinary Medical Association identifies cancer as a leading cause of death in older dogs and cats, and veterinary oncology organizations continue to emphasize earlier diagnosis, multimodal treatment, and quality-of-life preservation. These factors are positioning veterinary radiation oncology systems as strategic capital equipment for advanced animal hospitals competing on clinical outcomes, referral capture, and specialized care continuity.

Transformative Shifts in the Veterinary Radiation Oncology Landscape

The landscape is shifting from conventional multi-week radiation schedules toward hypofractionated, image-guided protocols that can be completed in fewer visits, often one to five fractions depending on tumor type, location, and clinician judgment. This shift is important for veterinary patients because anesthesia exposure, owner travel time, and overall treatment burden are major adoption considerations in companion animal oncology.

Technology convergence is also changing purchasing criteria. Modern veterinary stereotactic radiosurgery systems increasingly require integrated treatment planning software, cone-beam CT or comparable image guidance, rigid immobilization devices, dosimetry quality assurance, and trained radiation oncology teams. As a result, value is moving from standalone hardware toward end-to-end precision oncology workflows, service contracts, clinical training, and uptime assurance.

Cumulative Impact of Artificial Intelligence on Veterinary SRS

Artificial intelligence is beginning to influence veterinary stereotactic radiosurgery through image segmentation, organ-at-risk contouring support, deformable registration, treatment plan optimization, and quality assurance analytics. In human radiation oncology, peer-reviewed evidence shows that AI-assisted contouring can reduce manual planning time, but veterinary deployment remains dependent on species-specific datasets, clinical validation, and radiation oncologist oversight.

The cumulative impact of AI is therefore operational rather than fully autonomous. The strongest near-term value lies in standardizing workflows, reducing variability in planning steps, supporting adaptive review, and improving throughput for referral centers. Responsible adoption requires transparent model performance, audit trails, cybersecurity controls, and compliance with applicable medical device and data governance expectations in each jurisdiction.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America leads adoption because the United States and Canada have dense networks of specialty veterinary hospitals, board-certified veterinary oncologists, academic veterinary teaching hospitals, pet insurance penetration, and owner willingness to pursue advanced cancer care. Europe follows with strong clinical capability across the United Kingdom, Germany, France, Italy, and Spain, supported by established veterinary referral systems, advanced diagnostic imaging availability, and stringent radiation safety practices.

Asia-Pacific is gaining strategic importance as Japan, Australia, South Korea, China, and India expand companion animal healthcare infrastructure and specialty services, although access remains uneven outside major metropolitan areas. Latin America is led by Brazil and Mexico, where private veterinary groups and urban referral hospitals are developing advanced oncology capabilities. The Middle East is most active in high-income Gulf markets with premium veterinary centers and demand for high-acuity companion animal care, while Africa remains earlier-stage, with adoption concentrated in select urban and academic settings where imaging, radiotherapy infrastructure, and specialist availability can support safe delivery.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

Among major economic and policy groups, the G7 represents the strongest installed-base opportunity because it includes mature veterinary specialty markets, advanced imaging availability, established radiation safety governance, and high owner spending capacity. The European Union is important for harmonized safety expectations, cross-border technology procurement, professional mobility, and the presence of leading veterinary academic and referral institutions.

BRICS countries offer long-term growth potential through rising companion animal ownership, expanding middle-class spending, and investments in private veterinary infrastructure, but adoption depends on specialist training, radiotherapy facility development, and capital financing. ASEAN is emerging through urban premium pet care hubs, while GCC markets are attractive for high-acuity veterinary service models supported by affluent pet owners and advanced hospital developments. NATO countries overlap substantially with high-income markets, making them relevant for supply chain reliability, cybersecurity expectations, radiation safety compliance, and medical technology procurement standards.

Key Country Insights Across Major Veterinary Oncology Markets

The United States is the most commercially significant country market due to its concentration of specialty hospitals, veterinary oncologists, advanced imaging resources, and established referral pathways, while Canada benefits from similar clinical standards and proximity to North American technology and training ecosystems. Mexico and Brazil are the leading Latin American opportunities, with growth tied to metropolitan specialty practices, expanding private pet healthcare expenditure, and increasing demand for advanced companion animal oncology.

In Europe, the United Kingdom, Germany, and France offer advanced referral networks, strong clinical governance, and access to radiation oncology expertise, while Italy and Spain continue to build capacity in specialty oncology through urban referral centers. Russia has selected high-end veterinary centers but faces procurement, infrastructure, and technology access constraints. In Asia-Pacific, Japan, Australia, and South Korea show stronger readiness because of advanced imaging and specialty care capacity, China is scaling rapidly in urban pet hospitals as companion animal ownership and premium care demand increase, and India represents a longer-term opportunity driven by rising companion animal care demand and gradual specialty market development.

Actionable Recommendations for Industry Leaders

Industry leaders should position veterinary stereotactic radiosurgery as a complete clinical program rather than a single equipment sale. Successful commercialization requires integrated imaging, treatment planning, immobilization, delivery, dosimetry quality assurance, radiation safety support, training, and service coverage that helps hospitals safely treat complex tumors while managing anesthesia time and patient throughput.

Vendors and providers should prioritize evidence generation through multicenter clinical registries, tumor-specific outcome tracking, and standardized reporting of toxicity, local control, survival indicators, and quality-of-life measures. Commercial teams should also develop financing models, referral education, continuing education for veterinarians, and owner-facing communication tools to reduce adoption barriers and improve appropriate case volume.

Research Methodology

This executive summary is based on triangulated secondary research and industry validation using publicly available information from veterinary associations, radiation oncology guidelines, regulatory agencies, academic literature, clinical publications, medical device safety resources, and hospital network activity. Sources considered include organizations such as veterinary medical associations, veterinary radiology and radiation oncology bodies, veterinary oncology societies, animal medical device resources, international radiation safety materials, and peer-reviewed studies on stereotactic radiotherapy and AI in radiation oncology.

The analysis emphasizes verified clinical and industry indicators rather than unsupported forecasts. Regional and country assessments were developed by comparing companion animal healthcare maturity, specialist availability, radiotherapy infrastructure, imaging access, regulatory environment, radiation safety requirements, and observable investment in veterinary referral care.

Conclusion

Veterinary stereotactic radiosurgery systems are becoming central to the next phase of precision companion animal oncology. The market is supported by rising recognition of pet cancer, expanding specialty referral networks, wider access to advanced diagnostic imaging, and the clinical need for targeted treatments that reduce treatment burden while preserving quality of life.

Growth will favor organizations that combine validated technology, radiation oncology expertise, robust quality assurance, radiation safety discipline, and responsible AI-enabled workflow improvement. As adoption expands from North America and Europe into selected Asia-Pacific, Latin American, Middle Eastern, and African markets, leadership will depend on evidence, training, service reliability, cybersecurity readiness, and patient-centered oncology outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Veterinary Stereotactic Radiosurgery System Market, by Product Type

• 7.1. CyberKnife Systems
• 7.2. Gamma Knife Systems
• 7.3. Linear Accelerators (LINACs)
• 7.4. Proton Therapy Systems

8. Veterinary Stereotactic Radiosurgery System Market, by Technology

• 8.1. Image-Guided Radiosurgery (IGRS)
• 8.2. Intensity-Modulated Radiosurgery (IMRS)
• 8.3. Stereotactic Body Radiation Therapy (SBRT)
• 8.4. Volumetric Modulated Arc Therapy (VMAT)

9. Veterinary Stereotactic Radiosurgery System Market, by Animal Type

• 9.1. Canine
• 9.2. Equine
• 9.3. Feline

10. Veterinary Stereotactic Radiosurgery System Market, by Treatment Modality

• 10.1. Fractionated
• 10.2. Single-Session

11. Veterinary Stereotactic Radiosurgery System Market, by End User

• 11.1. Research Institutes
• 11.2. Specialty Clinics
• 11.3. Veterinary Hospitals

12. Veterinary Stereotactic Radiosurgery System Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Veterinary Stereotactic Radiosurgery System Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Veterinary Stereotactic Radiosurgery System Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Accuray Incorporated
• 16.2. Advanced Radiation Therapy
• 16.3. Avante Health Solutions
• 16.4. Best Theratronics Ltd
• 16.5. Brainlab AG
• 16.6. Canon Medical Systems Corp
• 16.7. CIVCO Radiotherapy
• 16.8. Elekta AB
• 16.9. GE HealthCare
• 16.10. Hitachi Ltd
• 16.11. IntraOp Medical
• 16.12. Ion Beam Applications SA
• 16.13. JPI Healthcare Solutions
• 16.14. Medtronic plc
• 16.15. Mitsubishi Electric Corporation
• 16.16. Nanovi AS
• 16.17. PetCure Oncology
• 16.18. Philips Healthcare
• 16.19. Radiance Medical Systems
• 16.20. RaySearch Laboratories
• 16.21. RefleXion Medical
• 16.22. Sedecal
• 16.23. Siemens Healthineers AG
• 16.24. United Imaging Healthcare
• 16.25. Universal Medical Systems
• 16.26. Varian Medical Systems Inc
• 16.27. ViewRay Inc
• 16.28. Xstrahl Ltd
• 16.29. ZAP Surgical Systems